Status:
COMPLETED
Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
Forest Laboratories
Conditions:
Obsessive Compulsive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess the efficacy of Escitalopram in the treatment of obsessive compulsive disorder and to determine the optimal treatment dose.
Detailed Description
Background and Purpose: Obsessive compulsive disorder affects approximately 3% of the population. Treatment options include the selective serotonin reuptake inhibitors (SSRIs), dual serotonin and nore...
Eligibility Criteria
Inclusion
- Diagnosis of OCD by DSM-IV
- Age 18-65
- Y-BOCS greater than 20
- Written informed consent
- Females of childbearing potential must have a negative serum or urinary beta-HCG test.
Exclusion
- Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception.
- Patients who, in the investigator's judgement, pose a serious suicidal or homicidal risk.
- Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease. Patients on anticoagulant therapy.
- History of seizure disorder
- Comorbid bipolar disorder, psychosis, organic mental disorder, or developmental disorder
- If there is a history of substance abuse, patients in remission at least 6 months.
- Currently being treated with behavioral therapy, specifically exposure and response prevention, for OCD.
- Other medications for medical disorders that may interfere with escitalopram
- Current major depression or prescribed an antidepressant for major depression within the past 12 months.
- Taken an SSRI medication within 2 weeks of beginning the study (4 weeks for fluoxetine).
- More than 1 adequate trial (at least 10 weeks at maximally tolerated dose) with another SSRI in the past.
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00116532
Start Date
October 1 2002
End Date
February 1 2007
Last Update
April 24 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital - OCD Clinic
Charlestown, Massachusetts, United States, 02129